MASTERCLASS IN PAEDIATRIC ONCOLOGY
14-18 October 2006, Orta San Giulio, Italy

Chair: R. Riccardi, IT - W.A. Kamps, NL - M.C.G. Stevens, UK
Educational Advisor: W. Gatzemeier, IT

An international faculty of experts delivering lectures focusing on bone tumours, soft-tissue sarcoma, neuroblastoma, central nervous system tumours and new drug development in the field of paediatric oncology.

In exclusive collaboration with SIOP Europe
An international faculty of experts delivering lectures focusing on bone tumours, soft-tissue sarcoma, neuroblastoma, central nervous system tumours and new drug development in the field of paediatric oncology.

Aims and objectives
ESO is pleased to announce the first Masterclass in Paediatric Oncology. This clinically-oriented educational programme has been designed for physicians who wish to improve their skills in the management of paediatric oncology patients. It is designed to offer a unique learning experience providing practice-oriented training.

Teaching format
The Masterclass offers plenary lectures focusing on state-of-the-art treatments and concluding with take-home messages, selected case presentations prepared by participants for discussion by the experts and interactive discussion between the participants and the faculty.
All participants will reside at the course venue and their participation is compulsory throughout the course.
The Masterclass will be entirely in English and fluency in English is necessary for admission.
TOPICS

BONE TUMOURS (osteosarcoma and Ewing sarcoma)
Session Leader: S. Bielack
- Epidemiology and genetics
- Staging and molecular markers
- Molecular pathology
- Current treatment programmes in Europe and in the US
- Critical issues

Case presentations and panel discussion

CENTRAL NERVOUS SYSTEM TUMOURS
Session Leader: R. Riccardi
- Epidemiology, genetics, pathology and molecular pathology
- Imaging
- Medulloblastoma
- Infants
- High-grade glioma
- Low-grade glioma
- Ependymoma
- Critical issues: Infants at what age?
  - Role of radiosurgery
  - Late effects
  - New active agents
- New radiation modalities
- Functional imaging

Case presentations and panel discussion
**NEUROBLASTOMA**
Session Leader: H.N. Caron

- Epidemiology and screening
- Pathology and embryology
- Molecular genetics
- Staging and prognostic classification
- Overview of treatment strategies in Europe and in the US
- High-risk treatment: Dose intensity during induction, myeloablative therapy, retinoic acid
- Low-risk treatment: Which groups not to treat?
- Novel strategies: MIGB, liposomes, new cytotoxics, targeted compounds

Case presentations and panel discussion

**NEW DRUG DEVELOPMENT**
Session Leaders: G. Vassal - B. Morland

- Preclinical strategy
- Disease-related targets
- Paediatric drug development
- EC regulations
- International network
- European Consortium: Innovative Therapies for Children with Cancer (ITCC)
- Ethics

Case presentations and panel discussion

**SOFT-TISSUE SARCOMA**
Session Leader: M.C.G. Stevens

**Rhabdomyosarcoma**

- Introduction: Epidemiology, pathology, molecular biology, staging and other prognostic variables
Current approaches to treatment of non-metastatic disease in Europe and North America: Overall strategies and chemotherapy combinations

Local control: Surgery and radiotherapy

Metastatic disease and new approaches to treatment

Synopsis: Controversies, questions and discussion

Non-rhabdo soft-tissue sarcoma

Introduction, classification, pathology

Synovial sarcoma

Extra-osseous Ewings / pPNET

Adult type sarcomas

Special histiotypes (infantile fibrosarcoma, malignant rhabdoid tumour, desmoplastic SRCT, fibromatoses, etc.)

Case presentations and panel discussion

**SPECIAL LECTURES:**

Supportive therapy

Late effects - Endocrine consequences of treatment: Implications for survivors in adult life

Late effects - Cardiotoxicity: The evidence base

<table>
<thead>
<tr>
<th>Time</th>
<th>Saturday 14 Oct</th>
<th>Sunday 15 Oct</th>
<th>Monday 16 Oct</th>
<th>Tuesday 17 Oct</th>
<th>Wednesday 18 Oct</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 - 13:30</td>
<td>Soft-tissue sarcoma</td>
<td>Bone tumours</td>
<td>Neuroblastoma</td>
<td>Central nervous system tumours part I</td>
<td>New drug development</td>
</tr>
<tr>
<td></td>
<td>Lunch break</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 - 16:30</td>
<td>Case presentations and panel discussion</td>
<td>Case presentations and panel discussion</td>
<td>Case presentations and panel discussion</td>
<td>Central nervous system tumours part II</td>
<td>Case presentations and panel discussion</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td>Special lecture</td>
<td>Special lecture Late effects - Endocrine consequences of treatment</td>
<td>Case presentations and panel discussion</td>
<td>Special lecture Late effects - Cardiotoxicity:</td>
<td></td>
</tr>
</tbody>
</table>


**GENERAL INFORMATION**

For information contact
Chatrina Melcher, European School of Oncology, ESO Bellinzona Office
IOSI, Ospedale Regionale Bellinzona e Valli, CH-6500 Bellinzona, Switzerland
Tel: +41 91 811 8050; fax: +41 91 811 8051; e-mail: masterclass@esoncology.org; www.cancerworld.org/eso

**INFORMATION AND APPLICATION FORM AVAILABLE AT: www.cancerworld.org/eso**

---

Application deadline: 15 June 2006

Accepted applicants are granted free registration.

Accommodation at the course venue (EUR 570 for the period 13-19 October) and travel will be covered by the participants.

---

**PARTICIPATION IN THE MASTERCLASS**

Admittance to the Masterclass is by competitive application.

**Ideal Masterclass candidate**
- Age between 30-40 years
- 2-4 years' experience in paediatric oncology
- Involvement in scientific activities and clinical trials
- Fluency in English

**How to apply**
Interested oncologists should submit an application form (available on-line at www.cancerworld.org/eso) with the following documents by the application deadline:

- Letter describing motivation for attending the Masterclass
- Short CV (maximum 2 pages) with list of recent publications
- Supporting letter from Head of Department / Mentor
- Abstract (1 page) with proposed presentation of a clinical case relating to one of the main subjects of the Masterclass (bone tumours, soft-tissue sarcoma, neuroblastoma, central nervous system tumours and new drug development in the field of paediatric oncology)

The abstract should be presented in the form of a grand-round clinical discussion rather than a publication report, and describe:
- Diagnostic considerations
- Treatment
- Outcome (follow-up)
- Up to three questions that the author proposes for discussion by the faculty and participants

**Travel grants**
A limited number of travel grants (to contribute to the cost of accommodation and travel) may be available to participants coming from countries defined as low- and lower-middle-income economies by the World Bank (http://www.worldbank.org/data/countryclass/classgroups.htm#Low_income)

The request for a travel grant must be mentioned in the letter accompanying the application, indicating the amount needed to cover travel costs.